Oncimmune Revenue and Competitors
Estimated Revenue & Valuation
- Oncimmune's estimated annual revenue is currently $9.3M per year.
- Oncimmune's estimated revenue per employee is $155,000
Employee Data
- Oncimmune has 60 Employees.
- Oncimmune grew their employee count by -9% last year.
Oncimmune's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Statistician | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, Head Business Development | Reveal Email/Phone |
5 | Director Quality and Regulatory Affairs | Reveal Email/Phone |
6 | Product Director | Reveal Email/Phone |
7 | Director Product Operations | Reveal Email/Phone |
8 | Senior Director Scientific Operations | Reveal Email/Phone |
9 | Director IP and Legal Services | Reveal Email/Phone |
10 | Chief Operating Officer | Reveal Email/Phone |
Oncimmune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is Oncimmune?
Oncimmune is a biotech company that specialises in blood tests and services that make use of the immune system. The EarlyCDT blood tests can detect cancer in the earliest stages when the body’s immune system is trying to fight it. The Company’s understanding of the immune system also means they’re able to work closely with pharmaceutical companies to ensure treatments, such as immunotherapy, are as effective and safe as possible.\n\nEarlyCDT Lung is the world’s most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor’s surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).
keywords:N/A
N/A
Total Funding
60
Number of Employees
$9.3M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oncimmune News
The award recognises Oncimmune as a leading developer of applied immunodiagnostics for the early detection of disease, drug discovery and...
Oncimmune will use its biomarker discovery platform, SeroTag, to identify autoantibodies that can be predictive of patient clinical response...
Oncimmune agrees two new commercial contracts. dl oncimmune holdings aim drug pharmaceuticals research services provider logo Oncimmune Holdings...
2 November 2021 Oncimmune Holdings plc ("Oncimmune", the "Company" and, together with its subsidiaries, the "Group") Full year results and progress update FY2021 revenues of £3.7 million (over 6x increase on FY2020) Continued delivery against three-year strategy, with FY2022 growth expected ...
Boulder-based Biodesix, Inc. is acquiring a Kansas lab run by Oncimmune Holdings, a global immunodiagnostics group, and is partnering with it to help commercialize its lung nodule malignancy risk test in the United States as part of an agreement valued at up to $28 million over the next five yea ...